A new study digs into the limited data available surrounding rare cancers. Overall, 20% of all patients diagnosed with cancer fall into the "rare cancer" classification, which affects Hispanic and Asian populations more others.
Axios has the scoop on this new research on rare cancers—in this case, "rare" is defined as fewer than six cases per 100,000 individuals per year. Some stats:
Compounding the data for what defines "rare" cancers is the fact molecular testing and a generally more complete understanding of different types of cancer is expanding the definition of cancer categories. The good news—understanding more specific cancer types can lead to more precise treatments and better outcomes.
The sheer amount of data and information provided by clinicaltrials.gov can be more of a burden instead of a benefit to patients looking for information applicable to their disease.
A partnership between cancer researcher—and stage 4 cancer patient—Dr. Tom Marsilje, a patient advocacy organization, and a technology company have helped other patients navigate clinical trial options more effectively. Utilizing only six fields, the site filters clinicaltrials(.gov) information by relevance to patients seeking trial information. The project highlights the advantages of combining skills and information between organizations in the cancer space to directly benefit patients.
"It's highly relevant because it will help us determine not only which men should be screened and how frequently, but also in the men who do develop tumors, it may give us information about novel treatment pathways that we may not have known or thought about in the past."
In one of the largest studies of its kind, researchers are beginning to scratch the surface of understanding prostate cancer genetics. In the study, men with BRCA mutations developed eight times as many cancers as compared to the general population.As we've covered in a previous Download, excessive testing has faced a backlash, often leading to unnecessarily painful, costly, and potentially harmful treatment for patients. However, this study out of the recent American Urological Association meeting supports the screening for male BRCA carriers to help provide more precise diagnosis and potential treatments.
The study, appearing online in Cancer Epidemiology, Biomarkers & Prevention, was the first to estimate how many women are living with advanced disease in the US.
Because of data gaps in cancer registries, it is difficult to know how many women are actually living with metastatic breast cancer in the US. A recent study concludes: